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LETTER TO THE EDITOR
Genetic screening for neovascular AMD: 
cost effective…not so quick
Elias Reichel* 
Abstract 
The following is a response to Brown and colleagues (Int J Retin Vitr 1:19, 2015), who analyzed the cost effectiveness 
of genetic screening for neovascular AMD in Category 3 (intermediate). As explained in this letter, it is premature to 
propose that genetic screening is cost effective in this setting. A simple clinical history and macular exam is highly 
cost effective and can easily guide screening strategies.
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Brown and colleagues [1] have analyzed the cost effective-
ness of genetic screening for neovascular AMD (NVAMD) 
in Category 3 (intermediate). Their analysis takes into 
account costs associated with genetic screening, follow-
up and early treatment as well as patient value gain based 
upon QALY (quality-adjusted life-year) gain. Their results 
show that genetic testing may be cost effective if an incre-
mental 4.5  % of NVAMD cases are identified early. I 
believe that this conclusion is flawed for two reasons.
First, the main premise of the paper is based upon the 
concept that models based on clinical history and phe-
notype are not as reliable as genetic models. However, 
there is strong evidence that the risk of progression to 
NVAMD can be assessed by clinical exam and history 
alone, and just as effectively as when genetic testing is 
incorporated into these models [2]. Therefore, the costs 
associated with genetic testing can be saved by using 
non-genetic models—a saving of two billion dollars that 
has yet to be incurred!
Second, Brown’s paper relies heavily on Yu et al.’s work 
[3] of models of genetic risk predicting progression to 
NVAMD. Genetic high risk Category 3 patients have a 
26 % chance of developing NVAMD in 10 years; Category 
2 patients have a 13 % chance of converting to NVAMD 
in 10 years. Because Brown’s work focuses on Category 3 
solely, they ignore a substantially large number of patients 
who may want genetic testing and if so identified as being 
high risk genetically would require very long-term follow-
up at presumably great expense. In other words, Category 
2 patients are greater in number and when identified as 
being at high risk genetically will need frequent long-term 
follow-up. This paper does not consider this population of 
patients—who I suspect may want to know their genotype 
if genetic screening became readily available. This would 
substantially change the calculus of the cost-effectiveness 
of genetic screening—likely making it less cost effective. 
Simply following Category 2 clinically as they convert to 
Category 3 is highly cost effective without the need for 
genetic testing. For these reasons it is extremely prema-
ture to propose that genetic screening is cost effective—
a simple clinical history and macular exam is highly cost 
effective and can easily guide screening strategies.
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